Compare C3.ai Inc (AI) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
C3.ai Inc vs BioNano Genomics Inc — how do they compare? C3.ai Inc trades at $10.23 (market cap $1.65B), while BioNano Genomics Inc trades at $1.2 (market cap $13.66M). The key difference: C3.ai Inc is far larger — about 120.8× BioNano Genomics Inc's market cap, and C3.ai Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| AI | BNGO | |
|---|---|---|
Market Cap | $1.65B | $13.66M |
Sector | Technology | Health |
52-Week High | $19.66 | $4.92 |
52-Week Low | $7.76 | $1.06 |
Enterprise Value | $1.08B | $16.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
C3.ai (AI) trades at $10.25, down 1.44% on the day, with mixed technical signals showing bullish moving averages but overbought RSI readings. The company maintains strong revenue growth, reaching $389 million in 2025, but continues to report significant losses with a -74.21% net margin. Recent positive developments include being named a Leader in AI Platforms by Forrester Research.
While technical indicators suggest short-term bullish momentum, fundamental challenges persist with consistent negative profitability. The stock faces execution risk in achieving profitability despite growing enterprise AI adoption. Analyst consensus remains cautious with only 21% buy ratings and a $10.20 price target slightly below current levels.
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About C3.ai Inc
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
